Bibliografía del artículo
1. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol 1979; 236:F321-32.
2. Reid IA, Schwartz J. Role of vasopressin in the control of blood pressure. In: Martini L, Ganong WF, eds. Frontiers in Neuroendocrinology. New York, NY: Raven Press; 1984:177-97.
3. Montani JP, Liard JF, Schoun J, Mohring J. Hemodynamic effects of exogenous and endogenous vasopressin at low plasma concentrations in conscious dogs. Circ Res 1980; 47:346-55.
4. Undesser KP, Hasser EM, Haywood JR, Johnson AK, Bishop VS. Interactions of vasopressin with the area postrema in arterial baroreflex function in conscious rabbits. Circ Res 1985; 56:410-7.
5. Luk J, Ajaelo I, Wong V, Wong J, Chang D, Chou L, Reid IA. Role of V1-receptors in the action of vasopressin on the baroreflex control of heart. Am J Physiol 1993; 265:R524-9.
6. Cowley AW Jr, Monos E, Guyton AC. Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ Res 1974; 34:505-14.
7. Mohring J, Glanzer K, Maciel JA Jr, Dusing R, Kramer HJ, Arbogast R, Koch-Weser J. Greatly enhanced pressor response to antidiuretic hormone in patients with impaired cardiovascular reflexes due to idiopathic orthostatic hypotension. J Cardiovasc Pharmacol 1980; 2:367-76.
8. Manning M, Sawyer WH. Antagonists of vasopressor and antidiuretic responses to arginine vasopressin. Ann Intern Med 1982; 96:520-2.
9. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000; 11:406-10.
10. Jackson EK. Vasopressin and other agents affecting the renal conservation of water. In Hardman JG, Limbird LE, Gilman AG (eds). Goodman & Gilman's pharmacological basis of therapeutics 9Ed, New York: McGraw Hill, 1996:715-31.
11. Lamping KG, Kanatuska H, Eastham CL, Chilian WM, Marcus ML. Nonuniform vasomotor responses of the coronary microcirculation to serotonin and vasopressin. Circ Res 1989; 65:343-51.
12. Katusic ZS, Shepherd JT, Vanhoutte PM. Vasopressin causes endothelium-dependent relaxations of the canine basilar artery. Circ Res 1984; 55:575-9.
13. Myers PR, Banitt PF, Guerra R Jr, Harrison DG. Characteristics of canine coronary resistance arteries: importance of endothelium. Am J Physiol 1989; 257(2 Pt 2):H603-H610.
14. Maturi MF, Martin SE, Markle D, Maxwell M, Burruss CR et al. Coronary vasoconstriction induced by vasopressin. Production of myocardial ischemia in dogs by constriction of nondiseased small vessels. Circulation 1991; 83:2111-21.
15. García Villalón AL, García JL, Fernández N, Monge L, Gómez B, Diéguez G. Regional differences in the arterial response to vasopressin: role of endothelial nitric oxide. Br J Pharmacol 1996; 118:1848-54.
16. Lee SL, Levitsky S, Feinberg H. Endogenous vasoconstrictor prostanoids: role in serotonin and vasopressin-induced coronary vasoconstriction. J Pharmacol Exp Ther 1991; 258:292-8.
17. Hupf H, Grimm D, Riegger GA, Schunkert H. Evidence for a vasopressin system in the rat heart. Circ Res 1999; 84:365-70.
18. Fernández N, García JL, García Villalón AL, Monge L, Gomes, B, Diéguez, G. Coronary vasoconstriction produced by vasopressin in anesthetized goats. Role of vasopressin V1 and V2 receptors and nitric oxide. Eur J Pharmacol 1988; 342:225-33.
19. Bax WA, Van der Graaf PH, Stam WB, Bos E, Nisato D, Saxena PR. [Arg8]vasopressin-induced responses of the human isolated coronary artery: effects of non-peptide receptor antagonists. Eur J Pharmacol 1995; 285:199-202.
20. Okamura T, Ayajiki K, Fujioka H, Toda N. Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries. J Hypertension 1999; 17:673-8.
21. Evora PR, Pearson PJ, Rodrigues AJ, Viaro F, Schaff HV. Effect of arginine vasopressin on the canine epicardial coronary artery:experiments on V1-receptor-mediated production of nitric oxide. Arq Bras Cardiol. 2003; 80:483-94.
22. Rees DD, Palmer RMJ, Hodson HF, Moncada, S. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol 1989; 96:418-24.
23. Moore PK, al-Swayeh OA, Chong NWS, Evans RA, Gibson A. L-NG-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br J Pharmacol 1990; 99:408-12.
24. Palmer RMJ, Rees DD, Ashton DS, Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophysic Res Comm 1988; 153:1251-6.
25. Kruszynsky M, Lammek B, Manning M. 1-(ß-Mercapto-ß,ß-ciclopentamethylenepropionic acid), 2-(O-methyl)tyrosine arginine vasopressin and 1-(ß-mercapto-ß,ß-ciclopentamethylenepropionic acid) arginine vasopressin, two highly potent antagonists of the vasopressor response to arginine vasopressin. J Med Chem 1980; 23:364-8.
26. Liard JF, Spadone JC. Hemodynamic effects of antagonists of the vasoconstrictor action of vasopressin in conscious dogs. J Cardiovasc Pharmacol 1984; 6:713-19.
27. Sawyer WH, Grzonka, Z, Manning M. Neurohypophyseal peptides. Design of tissue-specific agonists and antagonists. Molec Cell Endocrinol 1981; 22:117-34.
28. Ignarro LJ. Signal transduction mechanisms involving nitric oxide. Biochem Pharmacol 1991; 41:485-90.
29. Evora PR, Pearson PJ, Schaff HV. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest 1993; 103:1241-5.
30. Katusic ZS. Endothelial L-arginine pathway and regional cerebral arterial reactivity to vasopressin. Am J Physiol 1992; 262:H1557-H1562.
31. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000; 11:406-10.
32. De Aguilera EM, Via JM, Irurzun A, Martinez, MC, Cuesta MAM, Lluch S. Endothelium-independent contractions of human cerebral arteries in response to vasopressin. Stroke 1990; 21:1689-93.
33. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo, EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3', 5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981; 57:946-55.
34. Gruetter CA, Barry BK, MacNamara DB, Gruetter DY, Kadwitz PJ, Ignarro LJ. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside, and a carcinogenic nitrosamide. J Cyclic Nucleotide Res 1979; 5:211-24.
35. Leather HA, Segers P, Berends N, Vandermeersch E, Wouters PF. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med. 2002; 2548-52.
36. Morris DC, Dereczyk BE, Grzybowwski M, Martin GB, Rivers EP, Wotsman J, Amico JA. Vasopressin can increase coronary perfusion pressure during human cardiopulmonary resuscitation. Acad Emerg Med 1997; 4:878-83.
37. Wenzel V, Lindner KH, Krismer AC, Miller EA, Voleckel, WG, Lingnau W. Repeated administration of vasopressin but not epinephrine maintains coronary perfusion pressure after early and late administration during prolonged cardiopulmonary resuscitation in pigs. Circulation 1999; 99:1379-84.
38. Jeu LA, Cheng J. Cardiovascular Pharmacology. Vasopressin: new indications for an old drug Today in Cardiology, August 2001.
39. Faraci FM, Heistad DD. Regulation of large cerebral arteries and cerebral microvascular pressure. Circ Res 1990; 8-17.
40. Chen EP, Bittner HB, Kendall SWH, Vantrigt P. Hormonal and hemodynamic changes in a validated animal model of brain death. Crit Care Med 1996; 24:1352-1359.
41. Novitzky D, Cooper DKC, Wicomb WN. Electrocardiographic, hemodynamic, and endocrine changes occurring during experimental brain death in the Chacma baboon. J Heart Transplant 1984; 4:63-69.
42. Finkelstein I, Toledo-Pereyra LH, Castellanos J. Physiologic and hormonal changes in experimentally induced brain dead dogs. Transplant Proc 1987; 5:4156-4158.
43. Cintra EA, Maciel Junior JA, Araujo S, Castro M, Martins EF. Vasopressin and brain death. Arq Neuro-Psiquiatr 2000, 58:181-7.
44. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro DA, et al. Vasopressin deficiency in vasodilatory septic shock. Crit Care Med 1997; 25:1279-82.
45. Argenziano M, Chen JM, Choudhri AF, Culliname S, Garfein E, Weinberg AD, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998; 1169:973-80.
46. Holmes CL, Walley KR.Vasopressin in the ICU. Curr Opin Crit Care 2004; 10:442-8.
47. Albright TN, Zimmerman MA, Selzman CH. Vasopressin in the Cardiac Surgery Intensive Care Unit. Am J Crit Care 2002; 11:326-30.